Qol Holdings CoTSE:3034 +0.11%89 EBITDA Margin % is 19.96% as of Mar. 2026, which is 144% above its 10-year median of 8.17. GuruFocus rates TSE:3034 with a GF Score™ of 89/100 and a GF Value™ of 円2,274.64 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 668 Healthcare Providers & Services companies, Qol Holdings Co ranks worse than 55.54% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Qol Holdings Co's EBITDA for the
three
months ended in Mar. 2026 was 円14,923 Mil. Qol Holdings Co's Revenue for the
three
months ended in Mar. 2026 was 円74,747 Mil. Therefore, Qol Holdings Co's EBITDA margin for the quarter that ended in Mar. 2026 was 19.96%.
Qol Holdings Co (TSE:3034) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Qol Holdings Co EBITDA Margin % Related Terms
Qol Holdings Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Qol Holdings Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qol Holdings Co EBITDA Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Qol Holdings Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qol Holdings Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Qol Holdings Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Qol Holdings Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qol Holdings Co (TSE:3034) has a EBITDA Margin % of 19.96% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qol Holdings Co and its competitors. This is 144% above median its historical median of 8.17. Over the past decade, Qol Holdings Co's EBITDA Margin % has ranged from 7.21 to 8.74. According to the industry distribution chart, Qol Holdings Co ranks #371 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 55.5%.
Is Qol Holdings Co's EBITDA Margin % too high?
Qol Holdings Co's current EBITDA Margin % of 19.96% is 144% above median its 10-year median of 8.17. Over the past 10 years, this metric has ranged from a low of 7.21 to a high of 8.74. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Qol Holdings Co's value of 19.96% is 95.5% above this industry median. Based on the distribution chart, Qol Holdings Co ranks #371 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Qol Holdings Co has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qol Holdings Co's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Qol Holdings Co ranks #371 out of 668 companies for EBITDA Margin %. This places Qol Holdings Co in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Qol Holdings Co's value of 19.96% is 95.5% above this benchmark. Historically, Qol Holdings Co's own EBITDA Margin % has ranged from 7.21 to 8.74 over the past decade. While the company's 10-year median is 8.17 vs. the industry median of 10.21, Qol Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qol Holdings Co's current EBITDA Margin % of 19.96% is 95.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qol Holdings Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qol Holdings Co's current EBITDA Margin % is 19.96%, which is 144% above median its own 10-year median of 8.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qol Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Qol Holdings Co (TSE:3034) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,274.64, compared to a current price of 円1,822.00 — trading 19.9% below its estimated fair value. The current EBITDA Margin % is 19.96%, which is 144% above median its 10-year median of 8.17 and 95.5% above the Healthcare Providers & Services industry median of 10.21. Qol Holdings Co's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Qol Holdings Co (TSE:3034), the current EBITDA Margin % is 19.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qol Holdings Co (TSE:3034) Overvalued in 2026?
Based on GuruFocus' analysis, Qol Holdings Co stock appears to be undervalued.
The current stock price of 円1,822.00 is trading 19.9% below its estimated GF Value™ of 円2,274.64.
GuruFocus considers Qol Holdings Co to be Modestly Undervalued.
Key valuation signals for TSE:3034:
EBITDA Margin %: 19.96% (144% above median its 10-year median of 8.17)
GF Value™: 円2,274.64 vs. price of 円1,822.00 (19.9% below fair value)
Industry Position: 95.5% above the Healthcare Providers & Services median (#371 of 668)
No single metric tells the full story. See the TSE:3034 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qol Holdings Co Ltd provides pharmacy services under health insurance and sells pharmaceutical products. Its mission is to create healthy and comfortable living environments for everybody in those communities. The company operates through: Pharmacy and BPO segments. Under the Pharmacy segment the company puts customers first in-store development strategy, which is based on building one-on-one relationships with drug-prescribing clinics and hospitals in order to get the pharmacy services that include medical information. The BPO contracting segment includes clinical trials and projects and develops pamphlets and websites for medical institutions to promote sales of pharmaceutical products and provide advice on proper pharmaceutical product.
89GF Score
Get the complete analysis for TSE:3034
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3034 has been successfully added to your 
